Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Towards a Self-Administered Hearing Protection Regimen
NCT04826237Phase 4Terminated
- Sponsor
- Northwestern University
- Start
- Feb 2023
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of ulinastatin in sudden sensorineural hearing loss (SSHL), sponsored by Northwestern University. Started Feb 2023; status: terminated.
02
Drugs
ulinastatin
03
Conditions
sudden sensorineural hearing loss (SSHL)
Beyond the preview
Go deeper on NCT04826237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826237.